D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

NCT06643208 · clinicaltrials.gov ↗

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma

Interventions

DRUG: TACE-HAIC, Envafolimab and Lenvatinib

Sponsor

Fujian Provincial Hospital